The Rs 3,395 crore IPO of Anthem Biosciences has entered its second day of bidding, and all eyes are now on how the issue is performing across investor categories.
Let’s take a look at the GMP update, subscription numbers and other key detail of this ongoing mainboard issue –
Anthem Biosciences IPO: Grey Market Premium
On Day 2 of bidding, the Anthem Biosciences IPO is commanding a GMP of Rs 116 in the grey market. Based on the upper end of the price band of Rs 570, this translates to an estimated listing price of Rs 686, implying a 20.35% premium.
However, it’s important to remember that GMP is speculative, and actual listing price may vary depending on broader market sentiment closer to the debut.
Anthem Biosciences IPO: Day 2 subscription snapshot
As of Day 2, the IPO has been subscribed 1.22 times so far. The retail portion is subscribed 1.07 times, and Non-Institutional Investors (NIIs), subscribing 2.63 times. The Qualified Institutional Buyer (QIB) category stands at 0.40 times.
Anthem Biosciences IPO: Allotment, listing, and registrar details
The Anthem Biosciences IPO is set to close on July 16, 2025. The allotment of shares is expected to be finalised on July 17, 2025, with a tentative listing date of July 21, 2025, on both the BSE and NSE. The issue is being managed by JM Financial, while KFin Technologies is acting as the registrar for the IPO.
Anthem Biosciences IPO: What the analyst are saying
Brokerages are bullish on Anthem’s long-term prospects and are recommending a ‘Subscribe’ rating, even as some point to slightly higher valuations.
The brokerage firm Anand Rathi said, “The company has shown a profitable track record against its peers…We believe the company has potential to continue to grow its revenue and profitability ratios compared to its peers. Hence, we give a ‘SUBSCRIBE’ rating.”
Another brokerage firm Deven Choksey Research noted, “Even though the issue seems to be priced higher than the peer average, we believe it demands a premium led by stronger growth, industry leading margins, steady profitability and deep capability to produce complex products. We assign a ‘SUBSCRIBE’ rating.”
Motilal Oswal in its brokerage said, “Given the strong industry tailwinds, ABL is well positioned to capitalize on market opportunities through its capacity expansion…We recommend investors to ‘Subscribe’.”
Anthem Biosciences IPO: Company overview
The company was founded in 2006 and focused on Contract Research, Development, and Manufacturing Organization (CRDMO) with global reach. It offers integrated drug discovery, development, and manufacturing services.
Furthermore, it offerings include complex, fermentation-based APIs, such as peptides, enzymes, probiotics, vitamin analogues, and biosimilars. The company serves various client base, from emerging biotech startups to large pharmaceutical giants.